Therapy with the CAR T-cell remedy Yescarta (axicabtagene ciloleucel) continued to point out deep and sturdy responses, representing a probably healing therapy choice for sufferers with relapsed/refractory follicular lymphoma, in line with Dr. Sattva S. Neelapu.
Neelapu is a professor and deputy division chair within the Division of Lymphoma/Myeloma, Division of Most cancers Drugs, at The College of Texas MD Anderson Most cancers Heart, in Houston, in addition to a member of Graduate School, Immunology Program, Graduate Faculty of Biomedical Sciences, at The College of Texas Well being Science Heart, additionally positioned in Houston.
Neelapu sat down for an interview with CURE® to debate the five-year follow-up information from the part 2 ZUMA-5 trial evaluating the CAR T-cell remedy in sufferers with relapsed/refractory indolent non-Hodgkin lymphoma.
Transcript:
In contrast with different therapies which might be at the moment accessible for relapsed/refractory follicular lymphoma — together with therapies equivalent to [Rituxan (rituximab)] and [Revlimid (lenalidomide)], or [Rituxan] with chemotherapy equivalent to [Treanda (bendamustine)] or different chemotherapy regimens, [as well as] focused therapies equivalent to [Tazverik (tazemetostat)] or BTK inhibitors such [Brukinsa (zanubrutinib)] — we noticed that the sturdiness of response is way, for much longer with the CAR T-cell remedy Yescarta. The truth is, with many of the therapies, the median period of response is about one to 1 and a half years within the third-line setting and past for follicular lymphoma, whereas right here we’re seeing a five-year median period of response, which I believe is exceptional.
Most of those therapies usually are not thought of healing for follicular lymphoma, however primarily based on this five-year evaluation and the plateau within the lymphoma-specific progression-free survival [PFS], CAR T-cell remedy is probably healing for relapsed/refractory follicular lymphoma. Even in contrast with T cell engagers, that are extra lately permitted for follicular lymphoma, equivalent to mosunetuzumab which has a median period of response and a PFS within the two-year vary, whereas now we’re seeing five-year sturdiness of responses with CAR T-cell remedy.
Transcript was edited for readability and conciseness.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
